4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

Simple item page
dc.contributor.authorCardoso, Fatima V.
dc.contributor.authorSenkus, Elżbieta
dc.contributor.authorCosta, Alberto F.
dc.contributor.authorPapadopoulos, E.
dc.contributor.authorAapro, Matti S.
dc.contributor.authorAndré, Fabrice
dc.contributor.authorHarbeck, Nadia
dc.contributor.authorAguilar Lopez, B.
dc.contributor.authorBarrios, Carlos Henrique Escosteguy
dc.contributor.authorBergh, Jonas C.S.
dc.contributor.authorBiganzoli, Laura
dc.contributor.authorBoers-Doets, Christine Bettine
dc.contributor.authorCardoso, Maria João
dc.contributor.authorCarey, Lisa A.
dc.contributor.authorCorteś, Javier O.
dc.contributor.authorCurigliano, Giuseppe
dc.contributor.authorDié Ras, V.
dc.contributor.authorEl-Saghir, Nagi S.
dc.contributor.authorEniu, Alexandru E.
dc.contributor.authorFallowfield, Lesley J.
dc.contributor.authorFrancis, Prudence A.
dc.contributor.authorGelmon, Karen A.
dc.contributor.authorJohnston, Stephen R.D.
dc.contributor.authorKaufman, Bella
dc.contributor.authorKoppikar, Smruti B.
dc.contributor.authorKrop, Ian E.
dc.contributor.authorMayer, Musa
dc.contributor.authorNakigudde, Gertrude
dc.contributor.authorOffersen, Birgitte Vrou
dc.contributor.authorOhno, Shinji
dc.contributor.authorPagani, O.
dc.contributor.authorPaluch–Shimon, Shani
dc.contributor.authorPénault-Llorca, Fréd́erique M.
dc.contributor.authorPrat, Aleix
dc.contributor.authorRugo, Hope S.
dc.contributor.authorSledge, George W.
dc.contributor.authorSpence, Danielle
dc.contributor.authorThomssen, Christoph
dc.contributor.authorVorobiof, Daniel Alberto
dc.contributor.authorXu, Binghe
dc.contributor.authorNorton, Larry W.
dc.contributor.authorWiner, Eric P.Manuela
dc.contributor.departmentSpecialized Clinical Programs and Services
dc.contributor.departmentNaef K. Basile Cancer Institute (​NKBCI)
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:20:23Z
dc.date.available2025-01-24T12:20:23Z
dc.date.issued2018
dc.description.abstractAdvanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8]. © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
dc.identifier.doihttps://doi.org/10.1093/annonc/mdy192
dc.identifier.eid2-s2.0-85053909898
dc.identifier.pmid30032243
dc.identifier.urihttp://hdl.handle.net/10938/34273
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofAnnals of Oncology
dc.sourceScopus
dc.subjectAbc
dc.subjectAdvanced
dc.subjectBreast cancer
dc.subjectEso-esmo
dc.subjectGuidelines
dc.subjectMetastatic
dc.subjectBiomarkers, tumor
dc.subjectBiopsy, large-core needle
dc.subjectBreast
dc.subjectBreast neoplasms
dc.subjectChemoradiotherapy, adjuvant
dc.subjectClinical trials as topic
dc.subjectConsensus development conferences as topic
dc.subjectEurope
dc.subjectEvidence-based medicine
dc.subjectFemale
dc.subjectHumans
dc.subjectIntegrative medicine
dc.subjectMastectomy
dc.subjectMedical oncology
dc.subjectNeoadjuvant therapy
dc.subjectNeoplasm staging
dc.subjectSocieties, medical
dc.subjectTreatment outcome
dc.subjectAbemaciclib
dc.subjectAnthracycline derivative
dc.subjectAntineoplastic metal complex
dc.subjectBenzodiazepine derivative
dc.subjectBevacizumab
dc.subjectBiological response modifier
dc.subjectBisphosphonic acid derivative
dc.subjectBleomycin
dc.subjectCapecitabine
dc.subjectCyclophosphamide
dc.subjectDenosumab
dc.subjectEribulin
dc.subjectEverolimus
dc.subjectFulvestrant
dc.subjectGemcitabine
dc.subjectLapatinib
dc.subjectMethotrexate
dc.subjectOlaparib
dc.subjectOpiate
dc.subjectPalbociclib
dc.subjectPertuzumab
dc.subjectSteroid
dc.subjectTalazoparib
dc.subjectTamoxifen
dc.subjectTaxane derivative
dc.subjectTrastuzumab
dc.subjectTricyclic antidepressant agent
dc.subjectUnindexed drug
dc.subjectVinorelbine tartrate
dc.subjectZoledronic acid
dc.subjectTumor marker
dc.subjectAnxiety disorder
dc.subjectArticle
dc.subjectBone metastasis
dc.subjectBrain metastasis
dc.subjectBrain surgery
dc.subjectCancer fatigue
dc.subjectCancer immunotherapy
dc.subjectCancer palliative therapy
dc.subjectCancer radiotherapy
dc.subjectCancer recurrence
dc.subjectCancer staging
dc.subjectCancer surgery
dc.subjectChemotherapy induced nausea and vomiting
dc.subjectChemotherapy-induced peripheral neuropathy
dc.subjectConsensus
dc.subjectDiarrhea
dc.subjectDrug efficacy
dc.subjectDyspnea
dc.subjectEstrogen receptor positive breast cancer
dc.subjectHereditary tumor syndrome
dc.subjectHuman
dc.subjectHuman epidermal growth factor receptor 2 positive breast cancer
dc.subjectLiver metastasis
dc.subjectLiver toxicity
dc.subjectMale breast cancer
dc.subjectMalignant pleura effusion
dc.subjectMorbidity
dc.subjectNeutropenia
dc.subjectPersonalized medicine
dc.subjectPractice guideline
dc.subjectPriority journal
dc.subjectProgression free survival
dc.subjectRadiosurgery
dc.subjectSupport group
dc.subjectTriple negative breast cancer
dc.subjectTumor biopsy
dc.subjectTumor localization
dc.subjectAdjuvant chemoradiotherapy
dc.subjectBreast tumor
dc.subjectClinical trial (topic)
dc.subjectConsensus development
dc.subjectDiagnostic imaging
dc.subjectEvidence based medicine
dc.subjectGenetics
dc.subjectLarge core needle biopsy
dc.subjectMedical society
dc.subjectMetabolism
dc.subjectOncology
dc.subjectPathology
dc.subjectProcedures
dc.subjectSurgery
dc.title4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2018-8036.pdf
Size:
316.03 KB
Format:
Adobe Portable Document Format
Download

Collections

Specialized Clinical Programs and Services